fluoxetine has been researched along with Sex Disorders in 39 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sexual function during treatment with the selective noradrenaline reuptake inhibitor reboxetine, the selective serotonin reuptake inhibitor (SSRI) fluoxetine and placebo has been assessed in a multicentre, randomized, 8-week, double-blind study of 450 patients diagnosed with major depressive disorder." | 9.10 | Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. ( Brown, MT; Clayton, AH; Ferguson, JM; Filipiak-Reisner, JK; Schwartz, GE; Zajecka, J, 2003) |
| "This single-center, 12-week, double-blind, prospective, controlled-concentration study randomized 121 chronic back pain patients without major depression to active placebo (benztropine mesylate) or to predetermined low, medium, or high concentrations of desipramine (targets were 50, 110, and 150 ng/mL, respectively) or fluoxetine (targets were 100, 200, and 400 ng/mL, respectively)." | 5.12 | Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. ( Abramson, I; Atkinson, JH; Capparelli, EV; Garfin, SR; Matthews, SC; Slater, MA; Wallace, MS; Zisook, S, 2007) |
| " Sexual function during treatment with the selective noradrenaline reuptake inhibitor reboxetine, the selective serotonin reuptake inhibitor (SSRI) fluoxetine and placebo has been assessed in a multicentre, randomized, 8-week, double-blind study of 450 patients diagnosed with major depressive disorder." | 5.10 | Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. ( Brown, MT; Clayton, AH; Ferguson, JM; Filipiak-Reisner, JK; Schwartz, GE; Zajecka, J, 2003) |
| "Differences between the side effect profiles of clomipramine (CMI) and the selective serotonin reuptake inhibitors may be important factors in both treatment outcome and patient selection in obsessive-compulsive disorder (OCD)." | 5.09 | Side effects as predictors of drug response in obsessive-compulsive disorder. ( Ackerman, DL; Bystritsky, A; Greenland, S, 1999) |
| "Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders." | 4.82 | Safety and side effect profile of fluoxetine. ( Wernicke, JF, 2004) |
| "Adult outpatients with recurrent major depressive disorder were randomly assigned to receive venlafaxine extended release (ER; 75-300 mg/day) or fluoxetine (20-60 mg/day)." | 2.78 | Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. ( Dorries, KM; Dunner, DL; Gelenberg, AJ; Ninan, PT; Pedersen, R; Rothschild, AJ, 2013) |
| "Citalopram was ineffective only in 1 patient, which was discontinued after 4 weeks." | 2.75 | Salvage use of citalopram for treatment of fluoxetine-resistant premature ejaculation in recently married men: a prospective clinical trial. ( Baghinia, MR; Dadfar, MR, 2010) |
| "The aim of this study was to compare the efficacy of fluoxetine alone and combined with sildenafil in patients complaining of premature ejaculation." | 2.73 | Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. ( Hosseini, MM; Yarmohammadi, H, 2007) |
| "In men with premature ejaculation 90 mg fluoxetine weekly may be regarded as an effective and safe treatment." | 2.71 | Comparison of the efficacy and safety of 90 mg versus 20 mg fluoxetine in the treatment of premature ejaculation. ( Alcover Garcia, J; Gutierrez del Pozo, R; Manasia, P; Pomerol, J; Ribè, N, 2003) |
| "Fluoxetine, however, was more frequently associated with sexual dysfunction compared with bupropion SR." | 2.70 | A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. ( Ascher, J; Batey, S; Bolden-Watson, C; Book, MJ; Coleman, CC; Jamerson, B; King, BR; Metz, A; Richard, N; Segraves, RT, 2001) |
| "Treatment with sertraline was nearly as effective and had a lower incidence of side effects." | 2.69 | Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. ( Kim, SC; Seo, KK, 1998) |
| "Fluoxetine treatment produced significant improvements in self-visual analogue scale scores for sexual desire, anxiety for rapid ejaculation, and partner's satisfaction with ejaculation and overall sexual function." | 2.68 | An open clinical trial of fluoxetine in the treatment of premature ejaculation. ( Choi, HK; Kim, CH; Lee, HS; Song, DH, 1996) |
| " Moderate to high dosing was the only significant associated factor for FSD (odds ratio = 4." | 1.38 | Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine. ( Asmidar, D; Guan, NC; Hod, R; Sidi, H, 2012) |
| " Additionally, chronic administration of SSA-426, a molecule with dual activity as both a SSRI and 5-HT(1A) antagonist, did not produce deficits in non-contact penile erections at doses demonstrated to have antidepressant-like activity in the olfactory bulbectomy model." | 1.35 | 5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats. ( Andree, TH; Hughes, ZA; Malberg, JE; Pulicicchio, C; Rosenzweig-Lipson, S; Schechter, LE; Stack, GP; Sukoff Rizzo, SJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 14 (35.90) | 18.2507 |
| 2000's | 18 (46.15) | 29.6817 |
| 2010's | 5 (12.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gelenberg, AJ | 2 |
| Dunner, DL | 1 |
| Rothschild, AJ | 1 |
| Pedersen, R | 1 |
| Dorries, KM | 1 |
| Ninan, PT | 1 |
| Uphouse, L | 3 |
| Pinkston, J | 1 |
| Baade, D | 1 |
| Solano, C | 1 |
| Onaiwu, B | 1 |
| Zargooshi, J | 1 |
| Sukoff Rizzo, SJ | 1 |
| Pulicicchio, C | 1 |
| Malberg, JE | 1 |
| Andree, TH | 1 |
| Stack, GP | 1 |
| Hughes, ZA | 1 |
| Schechter, LE | 1 |
| Rosenzweig-Lipson, S | 1 |
| Ahrold, TK | 1 |
| Meston, CM | 1 |
| Birowo, P | 1 |
| Uckert, S | 1 |
| Kedia, GT | 1 |
| Scheller, F | 1 |
| Meyer, M | 1 |
| Taher, A | 1 |
| Rahardjo, D | 1 |
| Jonas, U | 1 |
| Kuczyk, MA | 1 |
| Dadfar, MR | 1 |
| Baghinia, MR | 1 |
| Sidi, H | 1 |
| Asmidar, D | 1 |
| Hod, R | 1 |
| Guan, NC | 1 |
| Kashani, L | 1 |
| Raisi, F | 1 |
| Saroukhani, S | 1 |
| Sohrabi, H | 1 |
| Modabbernia, A | 1 |
| Nasehi, AA | 1 |
| Jamshidi, A | 1 |
| Ashrafi, M | 1 |
| Mansouri, P | 1 |
| Ghaeli, P | 1 |
| Akhondzadeh, S | 1 |
| Clayton, AH | 1 |
| Zajecka, J | 1 |
| Ferguson, JM | 1 |
| Filipiak-Reisner, JK | 1 |
| Brown, MT | 1 |
| Schwartz, GE | 1 |
| Manasia, P | 1 |
| Pomerol, J | 1 |
| Ribè, N | 1 |
| Gutierrez del Pozo, R | 1 |
| Alcover Garcia, J | 1 |
| OZdel, O | 1 |
| Oğuzhanoğlu, A | 1 |
| Oğuzhanoğlu, NK | 1 |
| Karadağ, F | 1 |
| CUlha Atecí, F | 1 |
| Aybek, Z | 1 |
| Wernicke, JF | 1 |
| Metin, A | 1 |
| Kayigil, O | 1 |
| Ahmed, SI | 1 |
| Atkinson, JH | 1 |
| Slater, MA | 1 |
| Capparelli, EV | 1 |
| Wallace, MS | 1 |
| Zisook, S | 1 |
| Abramson, I | 1 |
| Matthews, SC | 1 |
| Garfin, SR | 1 |
| Hosseini, MM | 1 |
| Yarmohammadi, H | 1 |
| Sarkar, J | 2 |
| Hiegel, C | 2 |
| Ginis, GE | 1 |
| Hilbun, E | 1 |
| Waldinger, MD | 1 |
| Zwinderman, AH | 1 |
| Olivier, B | 1 |
| Schweitzer, DH | 1 |
| Maswood, N | 1 |
| Mercado, MG | 1 |
| Kimmer, SL | 1 |
| Holman, JR | 1 |
| Wanserski, G | 1 |
| Lo, V | 1 |
| Mattos, RM | 1 |
| Marmo Lucon, A | 1 |
| Srougi, M | 1 |
| Balon, R | 1 |
| Silverglat, MJ | 1 |
| Hopkins, HS | 1 |
| Benazzi, F | 1 |
| Mazzoli, M | 1 |
| Lee, HS | 1 |
| Song, DH | 1 |
| Kim, CH | 1 |
| Choi, HK | 1 |
| Evanoff, A | 1 |
| Newton, WP | 1 |
| Labbate, LA | 1 |
| Grimes, JB | 1 |
| Arana, GW | 1 |
| Kim, SC | 1 |
| Seo, KK | 1 |
| Hsieh, JT | 1 |
| Chang, HC | 1 |
| Law, HS | 1 |
| Hsieh, CH | 1 |
| Cheng, JT | 1 |
| Valmana, A | 1 |
| Purcell, P | 1 |
| Yilmaz, U | 1 |
| Tatlişen, A | 1 |
| Turan, H | 1 |
| Arman, F | 1 |
| Ekmekçioğlu, O | 1 |
| Ackerman, DL | 1 |
| Greenland, S | 1 |
| Bystritsky, A | 1 |
| Murat Başar, M | 1 |
| Atan, A | 2 |
| Yildiz, M | 1 |
| Baykam, M | 1 |
| Aydogănli, L | 2 |
| McMahon, CG | 1 |
| Samali, R | 1 |
| Başar, MM | 1 |
| Coleman, CC | 1 |
| King, BR | 1 |
| Bolden-Watson, C | 1 |
| Book, MJ | 1 |
| Segraves, RT | 1 |
| Richard, N | 1 |
| Ascher, J | 1 |
| Batey, S | 1 |
| Jamerson, B | 1 |
| Metz, A | 1 |
| Kline, MD | 1 |
| Lydiard, RB | 1 |
| George, MS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Antidepressants in Chronic Back Pain[NCT00018200] | Phase 2 | 130 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fluoxetine and Sex Disorders
| Article | Year |
|---|---|
Safety and side effect profile of fluoxetine.
Topics: Adolescent; Adult; Biotransformation; Bipolar Disorder; Cardiovascular Diseases; Child; Comorbidity; | 2004 |
Pharmacological treatment of premature ejaculation.
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Ejaculation; Fluoxetine; Humans; Male; Paroxetine; R | 1999 |
18 trials available for fluoxetine and Sex Disorders
| Article | Year |
|---|---|
Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols; | 2013 |
Effects of SNS activation on SSRI-induced sexual side effects differ by SSRI.
Topics: Adrenergic Agents; Adult; Arousal; Cross-Over Studies; Depressive Disorder; Double-Blind Method; Eph | 2009 |
Salvage use of citalopram for treatment of fluoxetine-resistant premature ejaculation in recently married men: a prospective clinical trial.
Topics: Adult; Citalopram; Drug Resistance; Ejaculation; Fluoxetine; Humans; Male; Marriage; Patient Satisfa | 2010 |
Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study.
Topics: Adolescent; Adult; Crocus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Huma | 2013 |
Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive | 2003 |
Comparison of the efficacy and safety of 90 mg versus 20 mg fluoxetine in the treatment of premature ejaculation.
Topics: Adult; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; | 2003 |
Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Back Pain; Capsules; Chronic Disease; Constipation; Desip | 2007 |
Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation.
Topics: Adult; Drug Therapy, Combination; Ejaculation; Fluoxetine; Humans; Male; Phosphodiesterase Inhibitor | 2007 |
Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Carbolines; Double-Blind Method; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; Phosphod | 2008 |
Fluoxetine-induced sexual dysfunction: a dose-dependent effect?
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Sexu | 1994 |
An open clinical trial of fluoxetine in the treatment of premature ejaculation.
Topics: Adult; Antidepressive Agents, Second-Generation; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; | 1996 |
Serotonin reuptake antidepressant effects on sexual function in patients with anxiety disorders.
Topics: 1-Naphthylamine; Adult; Anxiety; Ejaculation; Female; Fluoxetine; Humans; Libido; Male; Middle Aged; | 1998 |
Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents, Tricyclic; Clomipramine; Double-Blind Method; Ejacula | 1998 |
The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation.
Topics: Adult; Double-Blind Method; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; Prospective Studies; | 1999 |
Side effects as predictors of drug response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Anxiety; Clomipramine; Dose-Response Relationship, Drug; Ejaculation; Female; Flu | 1999 |
Comparison of sertraline to fluoxetine with regard to their efficacy and side effects in the treatment of premature ejaculation.
Topics: Adult; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; | 1999 |
Comparison of the efficacy of fluoxetine alone vs. fluoxetine plus local lidocaine ointment in the treatment of premature ejaculation.
Topics: Administration, Topical; Adult; Ejaculation; Fluoxetine; Humans; Lidocaine; Male; Middle Aged; Ointm | 2000 |
A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive | 2001 |
19 other studies available for fluoxetine and Sex Disorders
| Article | Year |
|---|---|
Use of an operant paradigm for the study of antidepressant-induced sexual dysfunction.
Topics: Animals; Antidepressive Agents; Conditioning, Operant; Disease Models, Animal; Dose-Response Relatio | 2015 |
Male sexual dysfunction in unconsummated marriage: long-term outcome in 417 patients.
Topics: Adolescent; Adult; Aged; Clomipramine; Erectile Dysfunction; Female; Fluoxetine; Follow-Up Studies; | 2008 |
5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats.
Topics: Aminopyridines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administrati | 2009 |
Evaluating the role of the serotoninergic system in the control of human seminal vesicle smooth muscle-an in vitro approach.
Topics: Adrenergic alpha-Agonists; Aged; Clomipramine; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, D | 2009 |
Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.
Topics: Adult; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Dose-Response Relationship, | 2012 |
A follow-up study of male sexual disorders: the neurophysiological assessments, anxiety-depression levels, and response to fluoxetine treatment.
Topics: Adult; Aged; Anxiety; Depression; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Sexual D | 2004 |
Does lidocaine ointment addition increase fluoxetine efficacy in the same group of patients with premature ejaculation?
Topics: Administration, Oral; Administration, Topical; Adult; Anesthetics, Local; Drug Therapy, Combination; | 2005 |
Subchronic treatment with fluoxetine attenuates effects of acute fluoxetine on female rat sexual behavior.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Estrous Cycle; Female; Fluoxetine; Ne | 2008 |
Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy.
Topics: Antidepressive Agents; Coitus; Data Interpretation, Statistical; Ejaculation; Fluoxetine; Fluvoxamin | 2008 |
Daily male exposure attenuates estrous cycle disruption by fluoxetine.
Topics: Animals; Biological Factors; Disease Models, Animal; Estrous Cycle; Female; Fluoxetine; Humans; Male | 2008 |
Clinical inquiries. What's the best drug treatment for premature ejaculation?
Topics: Anesthetics, Local; Antidepressive Agents; Clomipramine; Ejaculation; Fluoxetine; Humans; Lidocaine; | 2008 |
Fluoxetine and sexual dysfunction.
Topics: Fluoxetine; Humans; Sexual Dysfunction, Physiological | 1995 |
Fluoxetine and sexual dysfunction.
Topics: Fluoxetine; Humans; Sexual Dysfunction, Physiological | 1995 |
Fluoxetine and sexual dysfunction.
Topics: Fluoxetine; Humans; Sexual Dysfunction, Physiological | 1995 |
Treatment of premature ejaculation.
Topics: 1-Naphthylamine; Adult; Clomipramine; Ejaculation; Fluoxetine; Humans; Male; Patient Satisfaction; R | 1998 |
In vivo evaluation of serotonergic agents and alpha-adrenergic blockers on premature ejaculation by inhibiting the seminal vesicle pressure response to electrical nerve stimulation.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Clomipramine; Dose-Response Rel | 1998 |
Fluoxetine-terfenadine and sexual dysfunction.
Topics: Anti-Allergic Agents; Drug Therapy, Combination; Fluoxetine; Humans; Male; Selective Serotonin Reupt | 1998 |
Fluoxetine and anorgasmia.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive Diso | 1989 |
Fluoxetine-related anorgasmy.
Topics: Adult; Female; Fluoxetine; Humans; Male; Orgasm; Sexual Dysfunction, Physiological | 1989 |